BioLine Rx (FRA:YP2) Dividends Received


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.40
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.40
Price